Applying precision medicine and immunotherapy advances from oncology to host-directed therapies for infectious diseases

Frontiers in Immunology

Volumn 8, Issue JUN, 2017, Pages

  Mahon, Robert N ^a   Hafner, Richard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

HDT; Immuno oncology; Immunometabolism; Infectious diseases; Precision medicine; Tuberculosis

Indexed keywords

CHEMOKINE; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; HYPOXIA INDUCIBLE FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; SIRTUIN;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; FRANCISELLA TULARENSIS; HOST RESISTANCE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION; LEISHMANIA INFANTUM; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOLOGY; PATHOGEN LOAD; PERSONALIZED MEDICINE; PSEUDOMONAS AERUGINOSA; SEPTIC SHOCK; TOXOPLASMOSIS;

EID: 85021778908     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00688     Document Type: Article

References (39)

1. Antimicrobial Resistance: Global Report on Surveillance. Geneva, Switzerland: World Health Organization (2014). Available from: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1
2. Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol (2015) 15:255-63. doi:10.1038/nri3813
3. Palucka AK, Coussens LM. The basis of oncoimmunology. Cell (2016) 164:1233-47. doi:10.1016/j.cell.2016.01.049
4. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med (2015) 372:793-5. doi:10.1056/NEJMp1500523
5. Nossa CW, Blanke SR. Helicobacter pylori activation of PARP-1: usurping a versatile regulator of host cellular health. Gut Microbes (2010) 1:373-8. doi:10.4161/gmic.1.6.13572
6. Ba X, Gupta S, Davidson M, Garg NJ. Trypanosoma cruzi induces the reactive oxygen species-PARP-1-RelaA pathway for up-regulation of cytokine expression in cardiomyocytes. J Biol Chem (2010) 285:11596-606. doi:10.1074/jbc.M109.076984
7. Pereira JM, Harmon MA, Cossart P. A lasting impression: epigenetic memory of bacterial infections. Cell Host Microbe (2016) 19:579-82. doi:10.1016/j.chom.2016.04.012
8. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity (2013) 38:633-43. doi:10.1016/j.immuni.2013.04.005
9. O'Neil LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol (2016) 16:553-65. doi:10.1038/nri.2016.70
10. Tannahi GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al. Succinate is an inflammatory signal that induces IL-1ß through HIF-1a. Nature (2013) 496:238-42. doi:10.1038/nature11986
11. Wyatt EV, Diaz K, Griffin AJ, Rasmussen JA, Crane DD, Jones BD, et al. Metabolic reprogramming of host cells by virulent Francisella tularensis for optimal replication and modulation of inflammation. J Immunol (2016) 196:4227-36. doi:10.4049/jimmunol.1502456
12. Legendre C, Reen FJ, Mooij MJ, McGlacken GP, Adams C, O'Gara F. Psuedomonas aeruginosa alkyl quinolones repress hypoxia-inducibe factor 1 (HIF-1) signaling through HIF-1a degradation. Infect Immun (2012) 80:3985-92. doi:10.1128/IAI.00554-12
13. Chandrasekaran S, Cpaaron MG. The Streptococcus pyogenes NAD+glycohydrolase modulates epithelial cell PARylation and HMGB1 release. Cell Microbiol (2015) 17:1376-90. doi:10.1111/cmi.12442
14. Sun J, Siroy A, Lokareddy RK, Speer A, Doornbos KS, Cingolani G, et al. The tuberculosis necrotizing toxin kills macrophages by hydrolyzing NAD. Nat Struct Mol Biol (2015) 22:672-8. doi:10.1038/nsmb.3064
15. Eisenreich W, Heesemann J, Rudel T, Goebel W. Metabolic adaptations of intracellular bacterial pathogens and their mammalian host cells during infection ("Pathometabolism"). Microbiol Spectr (2015) 3(3):1-24. doi:10.1128/microbiolspec.MBP-0002-2014
16. Moreira D, Rodrigues V, Abengozar M, Rivas L, Rial E, Laforge M, et al. Leishmania infantum modulates host macrophage mitochondrial metabolism by hijacking the SIRT1-AMPK axis. PLoS Pathog (2015) 11:e1004684. doi:10.1371/journal.ppat.1004684
17. Charpentier T, Hammami A, Stäger S. Hypoxia inducible factor 1a: a critical factor the immune response to pathogens and Leishmania. Cell Immunol (2016) 309:42-9. doi:10.1016/j.cellimm.2016.06.002
18. Singh V, Kaur C, Chaudhary VK, Rao KV, Chatterjee S. M. Tuberculosis secretory protein ESAT-6 induces metabolic flux perturbations to drive foamy macrophage differentiation. Sci Rep (2015) 5:12906. doi:10.1038/srep12906
19. Singhal A, Jie L, Kumar P, Hong GS, Leow MK, Paleja B, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med (2014) 6(263):263ra159. doi:10.1126/scitranslmed.3009885
20. Hennessy E, Adams C, Reen FJ, O'Gara F. Is there potential for repurposing statins as novel antimicrobials. Antimicrob Agents Chemother (2016) 60:5111-21. doi:10.1128/AAC.00192-16
21. Parihar SP, Hartley MA, Hurdayal R, Guler R, Brombacher F. Topical simivastatin as host-directed therapy against severity of cutaneous leishmaniasis in mice. Sci Rep (2016) 6:33458. doi:10.1038/srep33458
22. Jayashankar L, Hafner R. Adjunct strategies for tuberculosis vaccines: modulating key immune cell regulatory mechanisms to potentiate vaccination. Front Immunol (2016) 7:577. doi:10.3389/fimmu.2016.00577
23. Arts RJ, Novakovic B, Ter Horst R, Carvalho A, Bekkering S, Lachmandas E, et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab (2016) 24:807-19. doi:10.1016/j.cmet.2016.10.008
24. Arts RJ, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, et al. Immunometabolic pathways in BCG-induced trained immunity. Cell Rep (2016) 17:2562-71. doi:10.1016/j.celrep.2016.11.011
25. Mahon RN, Hafner R. Immune cell regulatory pathways unexplored as host-directed therapeutic targets for Mycobacterium tuberculosis: an opportunity to apply precision medicine innovations to infectious diseases. Clin Infect Dis (2015) 61(Suppl 3):S200-16. doi:10.1093/cid/civ621
26. Robinson KS, Aw R. The commonalities in bacterial effector inhibition of apoptosis. Trends Microbiol (2016) 24:665-80. doi:10.1016/j.tim.2016.04.002
27. Conrad M, Angeli JP, Vandenabeele P, Stockwell BR. Regulated necrosis: disease relevance and therapeutic opportunities. Nat Rev Drug Discov (2016) 15:348-66. doi:10.1038/nrd.2015.6
28. Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer (2015) 15:457-72. doi:10.1038/nrc3973
29. Bengsch B, Johsnon AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8+ T cell exhaustion. Immunity (2016) 45:358-73. doi:10.1016/j.immuni.2016.07.008
30. Leone RD, Lo YC, Powell JD. A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J (2015) 13:265-72. doi:10.1016/j.csbj.2015.03.008
31. Attanasio J, Wherry EJ. Costimulatory and coinhibitory receptor pathways in infectious disease. Immunity (2016) 44:1052-68. doi:10.1016/j.immuni.2016.04.022
32. Barber DL, Mayer-Barber KD, Feng CG, Sharpe AH, Sher A. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol (2011) 186:1598-607. doi:10.4049/jimmunol.1003304
33. Singh A, Mohan A, Dey AB, Mitra DK. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon ?-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis (2013) 208:603-15. doi:10.1093/infdis/jit206
34. Karunarathne DS, Horne-Debets JM, Huang JX, Faleiro R, Leow CY, Amante F, et al. Programmed death-1 ligand 2-mediated regulation of the PD-L1 to PD-1 axis is essential for establishing CD4+ T cell immunity. Immunity (2016) 45:333-45. doi:10.1016/j.immuni.2016.07.017
35. Snelgrove RJ, Cornere MM, Edwards L, Dagg B, Keeble J, Rodgers A, et al. OX40 ligands fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection. J Infect Dis (2012) 205:975-83. doi:10.1093/infdis/jir868
36. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol (2016) 37:208-20. doi:10.1016/j.it.2016.01.004
37. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol (2012) 30:531-64. doi:10.1146/annurev.immunol.25.022106.141623
38. De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, et al. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol (2014) 4:349. doi:10.3389/fonc.2014.00349
39. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N Engl J Med (2014) 371:380-3. doi:10.1056/NEJMcibr1404664